{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Day+36+Assessments&page=5", "query": { "intervention": "Day 36 Assessments", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 166, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Day+36+Assessments&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Day+36+Assessments&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T05:12:02.438Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01871766", "title": "Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rhabdomyosarcoma" ], "interventions": [ { "name": "Vincristine", "type": "DRUG" }, { "name": "Dactinomycin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Surgical Resection", "type": "PROCEDURE" }, { "name": "Radiation", "type": "PROCEDURE" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Myeloid Growth Factor", "type": "DRUG" }, { "name": "Lymph Node Sampling", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "^1^1C-methionine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 115, "start_date": "2013-12-04", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871766" }, { "nct_id": "NCT00062439", "title": "S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 46, "start_date": "2003-07", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 154, "location_summary": "Mobile, Alabama • Fort Collins, Colorado • Jacksonville, Florida + 97 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062439" }, { "nct_id": "NCT03376477", "title": "Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "GM-CSF vaccine", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Prevnar13", "type": "DRUG" }, { "name": "Placebo Prevnar13", "type": "OTHER" }, { "name": "Placebo GM-CSF Vaccine", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2019-09-23", "completion_date": "2025-05-30", "has_results": true, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03376477" }, { "nct_id": "NCT04216342", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "Fx-5A peptide complex", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 64, "start_date": "2021-09-29", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04216342" }, { "nct_id": "NCT02904629", "title": "Evaluation of Respecting the Circle of Life on Pregnancy Prevention Outcomes Among American Indian Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sex", "Unprotected Sex", "Contraception", "Alcohol Use", "Drug Use", "Pregnancy" ], "interventions": [ { "name": "Respecting the Circle of Life (RCL)", "type": "BEHAVIORAL" }, { "name": "Control Program", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Johns Hopkins Bloomberg School of Public Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": null, "sex": "ALL", "summary": "11 Years and older" }, "enrollment_count": 1072, "start_date": "2016-05", "completion_date": "2022-04", "has_results": false, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 1, "location_summary": "Whiteriver, Arizona", "locations": [ { "city": "Whiteriver", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02904629" }, { "nct_id": "NCT04660760", "title": "Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Unresectable Gastric Adenocarcinoma", "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2021-06-16", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2024-04-01", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660760" }, { "nct_id": "NCT00547508", "title": "To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Impotence" ], "interventions": [ { "name": "tadalafil", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 485, "start_date": "2002-10", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2007-10-22", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00547508" }, { "nct_id": "NCT01196390", "title": "Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Stage IB Esophageal Cancer AJCC v7", "Stage IIA Esophageal Cancer AJCC v7", "Stage IIB Esophageal Cancer AJCC v7", "Stage IIIA Esophageal Cancer AJCC v7", "Stage IIIB Esophageal Cancer AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2011-02-14", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 634, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01196390" }, { "nct_id": "NCT04305184", "title": "A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Tympanic Membrane Perforation" ], "interventions": [ { "name": "ASP0598", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 36, "start_date": "2020-09-10", "completion_date": "2023-01-24", "has_results": true, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 10, "location_summary": "Palo Alto, California • Torrance, California • Boca Raton, Florida + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "New Albany", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305184" }, { "nct_id": "NCT03171168", "title": "The Effect of AposTherapy on Knee Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Knee Osteoarthritis", "Knee Pain" ], "interventions": [ { "name": "AposTherapy", "type": "DEVICE" }, { "name": "Traditional Physical Therapy", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 54, "start_date": "2016-11-30", "completion_date": "2019-12-30", "has_results": true, "last_update_posted_date": "2022-12-14", "last_synced_at": "2026-10-09T05:12:02.438Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03171168" } ] }